An exploratory clinical trial from the University of Pittsburgh suggests that low‑dose oral lithium may help slow the decline of verbal memory, or ability to remember and recall words and sentences, in older adults with mild cognitive impairment, particularly among those with evidence of amyloid beta—one of the hallmark biomarkers of Alzheimer’s disease.

Despite recent FDA approvals of amyloid-targeting antibodies, reversing Alzheimer's disease (AD) remains an ultimate challenge. A new review highlights the shift from single-target treatments to holistic strategies, integrating Tau pathology, genetics, aging, and systemic health factors to pave the way for next-generation interventions.